| Market Capitalization (Millions $) |
6 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
2 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-1 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Aptorum Group Limited is a pharmaceutical company based in Hong Kong. The company was founded in 2017 and is specialized in the discovery, development, and commercialization of therapeutic and diagnostic technologies and products. Aptorum Group Limited is publicly listed on the NASDAQ under the ticker symbol APM.
The company's mission is to address unmet medical needs through scientific innovation and entrepreneurship. Aptorum Group Limited focuses on developing treatments for infectious diseases, neurological disorders, and cancer patients. The company has a diversified pipeline of drug candidates, diagnostic and medical devices, as well as innovative solutions for microbiome-related conditions.
One of the company's flagship projects is the development of its lead drug candidate, SACT-1, a novel targeted antimicrobial peptide for the treatment of drug-resistant infections caused by gram-negative bacteria. Aptorum Group Limited has also developed preclinical drug candidates for the treatment of breast cancer, pancreatic cancer, Alzheimer's disease, and other neurological indications.
Aptorum Group Limited has partnerships and collaborations with a network of academic, scientific, and biotech organizations to accelerate the development of its technologies and products. The company has established strategic collaborations with key opinion leaders, academic institutions, and research centers in the US and Asia.
In addition to its drug development programs, Aptorum Group Limited is also actively pursuing innovative diagnostics and medical devices. The company is developing a diagnostic tool for the detection of bacterial infections in clinical settings, as well as medical devices for the treatment of infectious and dermatological conditions.
Aptorum Group Limited's management team is comprised of experienced pharmaceutical executives with a proven track record of successful product development and commercialization. The company's scientific advisory board consists of world-renowned experts in microbiology, immunology, oncology, and neuroscience.
Overall, Aptorum Group Limited is a forward-thinking pharmaceutical company with a diverse pipeline of innovative therapies for unmet medical needs. The company is well-positioned to make significant contributions to the scientific and medical community through pioneering research and development efforts.
Company Address: 17 Hanover Square London 0
Company Phone Number: 20 8092 9299 Stock Exchange / Ticker: NASDAQ APM
|
%
0.47%